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Abstract
Background: The cytoplasmic tyrosine kinase, Src, has been found to play a crucial role in VEGF
(vascular endothelial growth factor) – dependent vascular permeability involved in angiogenesis.
The two main VEGFRs present on vascular endothelial cells are KDR/Flk-1 (kinase insert domain-
containing receptor/fetal liver kinase-1) and Flt-1 (Fms-like tyrosine kinase-1). However, to date, it
has not been determined which VEGF receptor (VEGFR) is involved in binding to and activating Src
kinase following VEGF stimulation of the receptors.
Results: In this report, we demonstrate that Src preferentially associates with KDR/Flk-1 rather
than Flt-1 in human umbilical vein endothelial cells (HUVECs), and that VEGF stimulation resulted
in an increase of Src activity associated with activated KDR/Flk-1. These findings were determined
through immunoprecipitation-kinase experiments and coimmunoprecipitation studies, and were
further confirmed by GST-pull-down assays and Far Western studies. However, Fyn and Yes, unlike
Src, were found to associate preferentially with Flt-1.
Conclusions: Thus, Src preferentially associates with KDR/Flk-1, rather than with Flt-1, upon
VEGF stimulation in endothelial cells. Our findings further highlight the potential significance of
upregulated KDR/Flk-1-associated Src activity in the process of angiogenesis, and help to elucidate
more clearly the specific roles and mechanisms involving Src family tyrosine kinase in VEGF-
stimulated signal transduction events.
Background
Angiogenesis is a process that is of critical importance to
tumorigenesis and tumor metastasis, as well as to the
growth and maintenance of normal vasculature. Both the
processes of angiogenesis and tumorigenic proliferation
are key events essential for the successful growth of vascu-
larized tumors. Indeed, inhibition of neovascularization
has been shown to abolish or slow tumor growth in vari-
ous experimental models [1,2]. Angiogenesis plays both
beneficial and detrimental roles in normal and disease
processes. For example, abnormally enhanced angiogenic
responses are observed during conditions such as diabetic
retinopathy and rheumatoid arthritis [3]. On the other
hand, promotion of the angiogenic response has been
demonstrated to be beneficial in treating ischemic condi-
tions, such as myocardial ischemia/infarction [4]. Thus, a
comprehensive understanding of the molecular mecha-
nisms underlying the angiogenic response may help in
preventing and treating many diseases displaying aberrant
angiogenesis.
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VEGF is an angiogenic factor that is very closely associated
with the induction and maintenance of neovasculature in
human cancers. Although other splice variant forms of
VEGF have been discovered to be encoded and expressed,
VEGF-A165 remains the main biologically relevant splice
form. VEGF-A165 is produced from tumor cells and strom-
al fibroblast cells [5], and is able to bind both KDR/Flk-1
and Flt-1 (two main VEGF receptors of the VEGF family
expressed by vascular endothelial cells) [6–8]. VEGF-A165
exhibits two major biological activities. One, is that it pro-
motes increased microvascular hyperpermeability to cir-
culating plasma proteins (one of the steps important in
early vasculogenesis) [9,10]. This leads to extravasation of
fibrinogen and other plasma proteins, activation of the
clotting system, and deposition of a fibrin gel in the ex-
travascular space. The fibrin gel provides a proangiogenic
matrix that favors and supports the migration of fibrob-
lasts and the growth of new blood vessels [11–13]. Anoth-
er major biological activity of VEGF-A165 is its ability to
stimulate vascular endothelial cell proliferation [14–16].
The VEGF receptors, KDR/Flk-1 and Flt-1, are receptor ty-
rosine kinases structurally related to receptors of the Fms/
Kit/PDGFR family. Both VEGFRs contain a large insert se-
quence in their respective intracellular kinase domains
and seven immunoglobulin-like domains in their respec-
tive NH2-terminal regions. Also, both KDR/Flk-1 and Flt-
1 have been shown to be expressed mainly on endothelial
cells [6,7], and to play important roles in transducing sig-
nals upon VEGF stimulation of the endothelium. Previous
knockout studies have demonstrated that KDR/Flk-1 (-/-)
mice exhibit embryonic lethality (at E8.5-E9.0). They ex-
hibit no development of blood vessels and very low he-
matopoiesis [17]. Flt-1 (-/-) mice also exhibit embryonic
lethality (at E8.5), but as a result of overgrowth of en-
dothelial cells and disorganization of blood vessels [18].
This suggests that at least in the early stages of embryogen-
esis, KDR/Flk-1 is essential for both proliferation and dif-
ferentiation of endothelial cells, whereas Flt-1 can
potentially act as a negative regulator of cell proliferation
in the assembly of the vascular endothelium [19]. These
and other observations indicate that KDR/Flk-1 and Flt-1
may have different biological functions, and suggest that
they may utilize different downstream signaling path-
ways.
Src is a cytoplasmic protein tyrosine kinase, whose activa-
tion and recruitment to perimembranal signaling com-
plexes has important implications for cellular fate. It has
well-documented that Src protein levels and Src kinase ac-
tivity are significantly elevated in human breast cancers
[20,21], colon cancers [22–24], and pancreatic cancers
[25,26] as well. Furthermore, activation of Src by growth
factors and growth factor receptors, such as PDGF(R),
EGF(R), and HER2/Neu, has been shown to promote cell
proliferation [27–30]. The biological importance of Src in
the VEGF angiogenic system was published in a report by
Eliceiri and collaborators [31]. Their experiments used a
CAM model (chick embryo chorioallantoic membrane
model) and a murine subcutaneous angiogenesis model
to demonstrate a crucial role for Src in VEGF-dependent
vascular permeability. Also, Suarez and Ballmer-Hofer
proposed from their study that VEGF-mediated disruption
of gap junctional communication in endothelial cells via
Src was the cause of local increased endothelial permea-
bility [32].
To date, it has been assumed that Src becomes activated in
endothelial cells following binding to an activated VEGF
receptor [33]. However, it is not known whether Src binds
and is activated by one VEGFR or is able to bind and be
activated by both VEGFRs to a substantial degree. Our
study reveals that Src preferentially associates with and is
subsequently activated by KDR/Flk-1 rather than with Flt-
1 in HUVECs (human umbilical vein endothelial cells).
Results and Discussion
Coimmunoprecipitation of Src activity with KDR/Flk-1
A potentially important biological role for Src in VEGF-de-
pendent vascular permeability has been previously report-
ed [31,33]. However, it is not known if one or both of the
main endothelial VEGF receptors (VEGFRs) are specifical-
ly able to bind to and activate Src. We compared the abil-
ity of the two main types of endothelial VEGFRs (KDR/
Flk-1 and Flt-1) to associate with and activate Src upon
VEGF treatment, by determining whether Src activity
could be coimmunoprecipitated with either receptor (Fig.
1A). HUVECs were either serum-starved, or serum-starved
and then treated with VEGF, or lysed (unstarved, untreat-
ed) at subconfluence. Cell extracts of these samples were
then immunoprecipitated using α-KDR/Flk-1 (N-931), α-
Flt-1 (H-225), or nonimmune rabbit IgG; and kinase as-
says were performed using these immunocomplexes.
Upon VEGF treatment, both KDR/Flk-1 and Flt-1 become
tyrosine-phosphorylated (Fig 1B). This is accompanied by
a 2.15-fold increase in phosphorylation of a 60 kDa pro-
tein (corresponding to the molecular weight of Src) asso-
ciated with KDR/Flk-1 and a 1.71-fold increase in enolase
substrate phosphorylation activity associated with the
KDR/Flk-1 immunocomplexes (Fig. 1A). However, there
was very little detectable p60 kDa phosphorylation or
enolase substrate phosphorylation activity associated
with the Flt-1 immunocomplexes. Yet, Flt-1 was found to
be immunoprecipitatable and tyrosine-phosphorylated
upon VEGF treatment (Fig. 1B, left panel). Also, nonim-
mune rabbit IgG did not coprecipitate any significant lev-
els of p60 kDa phosphorylation or enolase substrate
phosphorylation. Kinase reactions were also performed
on Src optimal peptide substrate (AEEEIYGEFEAKKKK
[34]) with similar results (unpublished observations).BMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/32
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Time-dependent VEGF stimulation of Src association with 
KDR/Flk-1
In order to further study the specificity and time-course of
Src association with KDR/Flk-1, HUVECs (human umbil-
ical vein endothelial cells) were serum-starved and then
treated with VEGF (15 ng/mL) for 0, 15, 30, 60, or 120
min. As seen in Figure 2A, Src association with KDR/Flk-1
peaked around 15 min of VEGF treatment. Concurrently,
KDR/Flk-1 phosphorylation initially increased and then
decreased, peaking at about 15 minutes (Fig. 2B). Our re-
sults also indicate that the association of activated Src
phosphorylated on tyrosine 419 with KDR/Flk-1 peaked
at approximately 15 minutes of VEGF treatment. This was
detected by α-Src phosphotyrosine 419 specific Src anti-
body that is able to detect an activated form of c-Src (Fig.
2B). Because of logistical considerations, we did not ex-
amine time points between 0 and 15 minutes. Therefore,
we cannot exclude the possibility that a substantial level
Figure 1
Src Activity coprecipitates with KDR/Flk-1. (A) HUVECs were either serum-starved (-), or starved and then VEGF-
treated (15 ng/mL VEGF for 15 min.) (+), or lysed (unstarved, untreated) at subconfluence (C). Cell extracts of these samples 
were immunoprecipitated using α-Flt-1 (H-225), α-KDR/Flk-1 (N-931), or rabbit nonimmune IgG. Kinase assay reactions were 
subsequently performed using enolase substrate. Samples were resolved on 10% SDS-PAGE gels. The gels were treated with 1 
M KOH at 55°C for 1 h after electrophoresis to remove background due to serine phosphorylation. The gels were then dried 
and exposed to autoradiographic film (upper panel). (B) Cell extracts from the indicated treatment conditions were immuno-
precipitated using α-Flt-1 (H-225) and immunoblotted using α-phosphotyrosine (4G10) or α-Flt-1 (H-225) (left panel); or the 
cell extracts were immunoprecipitated using α-KDR/Flk-1 (A-3) and immunoblotted using α-phosphotyrosine (4G10) or α-
KDR/Flk-1 (N-931) (right panel).
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of activation of KDR/Flk-1 and Src did not also occur at
these earlier times.
We also studied the time course of Src association with Flt-
1. However, we did not find detectable Src association
with Flt-1 up to 120 minutes after VEGF treatment (Fig.
2C). At the same time it was evident that Flt-1 was phos-
phorylated upon VEGF treatment (Fig. 2D). These results
suggested to us that Src preferentially associated with
KDR/Flk-1 rather than Flt-1 upon VEGF treatment.
Src SH3-SH2 association with KDR/Flk-1 increases upon 
VEGF stimulation
In order to confirm Src preference for interaction with Flk-
1/KDR compared to Flt-1, we tested GST-Src domain fu-
sion constructs for their ability to bind to KDR/Flk-1 in
GST-pull-down experiments. The results indicated that
VEGF-stimulated KDR/Flk-1 was able to bind strongly to
constructs containing both the Src SH3 and SH2 domains
(Fig. 3A). Some basal binding of KDR/Flk-1 to the Src
SH3-SH2 and Src U-SH3-SH2 was observed, although the
extent of this binding was less than the binding observed
after VEGF treatment. The Src unique domain alone was
not able to bind to KDR/Flk-1, but it seemed to augment
binding when present in a construct containing both the
Src SH3 and SH2 domains (Fig. 3A). Notably, however,
upon VEGF stimulation and tyrosine phosphorylation of
KDR/Flk-1, the ability of KDR/Flk-1 to bind to Src SH3-
SH2 was increased.
In contrast, when we tested the same panel of GST-Src do-
main fusion proteins for their ability to bind to Flt-1, we
did not observe detectable binding of Flt-1 with the GST-
Src domain fusion proteins (Fig. 3A). Levels of Flt-1 were
equivalent in serum-starved versus VEGF-treated cells, and
Flt-1 exhibited tyrosine phosphorylation upon VEGF
treatment (Fig. 3C). These data revealed that Flt-1 was
present and detectable in lysate from HUVECs, but was
not able to interact with the major protein binding do-
mains of Src. Thus, this data further supports a binding
preference of Src for KDR/Flk-1 following VEGF stimula-
tion.
To further confirm that VEGF treatment leads to an in-
creased ability of tyrosine phophorylated KDR/Flk-1 to in-
teract with Src SH3-SH2, we performed Far Western
experiments (Fig. 3D). HUVECs were either serum-
starved, or starved and then treated with VEGF. Following
immunopreciptiation of cell extracts using α-KDR/Flk-1
antibody, biotinylated GST-Src fusion proteins were used
in immunoblotting. Figure 3D demonstrates that KDR/
Flk-1 exhibits increased interaction with Src SH3-SH2 do-
mains after stimulation of HUVECs with VEGF, and after
tyrosine phosphorylation of KDR/Flk-1. Levels of KDR/
Flk-1 protein remained similar before and after VEGF
treatment, and there was an increase in tyrosine phospho-
rylation of KDR/Flk-1 after VEGF treatment. Control ex-
periments indicated that KDR/Flk-1 (prior to VEGF
treatment and post-VEGF treatment) did not interact with
biotinylated-GST alone (Fig. 3D).
At this time, we do not know the exact nature of the bind-
ing interactions between Src and KDR/Flk-1. However, we
have observed that both the Src SH2 and SH3 domains
appear to be required for optimal binding to KDR/Flk-1
(data not shown). It is possible to speculate that VEGF
binding and stimulation of KDR/Flk-1 confers the proper
conformation to KDR/Flk-1 such that it is able to initially
bind the Src SH3 domain via the cytoplasmic KDR/Flk-1
proline-rich regions and/or KDR/Flk-1 phosphotyrosine
sites. When Src is able to bind to this accessible KDR/Flk-
1 region, the Src protein itself may be further opened up
by Src SH2 domain binding to a phosphotyrosine site on
KDR/Flk-1, and Src's active site might then be made fully
available for further propagation of transducing cellular
signals. Thus in this manner, the binding interactions be-
tween KDR/Flk-1 and Src SH3 and Src SH2 domain of Src
would act to facilitate disruption of intramolecular, inhib-
itory Src SH3/SH2 interactions. This would ultimately al-
low Src to open up into an active conformation, thereby
permitting autophosphorylation on Src Tyr 419 [35], and
also upregulation of Src activity by dephosphorylation of
negative-regulatory C-terminal phosphotyrosine 530 by
phosphatases [36–39]. We are currently conducting fur-
ther studies to investigate this model for Src-KDR/Flk-1 in-
teraction. Although we did not detect GST-Src unique
domain association with KDR/Flk-1, the presence of the
Src unique domain together with Src SH3-SH2 did in-
crease the extent of the Src-KDR/Flk-1 interaction. At
present, we do not know the basis for this enhanced level
of binding. However, it is notable that both GST-Unique-
SH3-SH2 and GST-SH3-SH2 Src display enhanced associ-
ation with VEGF-stimulated, tyrosine-phosphorylated
KDR/Flk-1 compared to unstimulated KDR/Flk-1.
Our findings suggest that the Src SH3 domain together
with the Src SH2 domain is able to interact with KDR/Flk-
1. Src family SH3 domains preferentially bind proline-
rich motifs with the sequence RPLPXXPX [40]. The opti-
mal Src SH2 binding consensus sequence is ΦpYEEI/Φ
(where Φ = hydrophobic amino acids, and E = glutamate
or other hydrophilic amino acids) [34,41]. Significantly,
several such potential Src-binding sites are present on the
C-terminal cytoplasmic domain of KDR/Flk-1. A candi-
date proline-rich, SH3-binding, consensus sequence exists
in KDR/Flk-1 at amino acid region 1192–1198. Also, sev-
eral tyrosine phosphorylation sites exist in KDR/Flk-1.
Previously, Cunningham et al. [42] have shown that tyro-
sine residues 801 (juxtamembranal) and 1175 (C-termi-
nal) were phosphorylated on KDR/Flk-1. TyrosineBMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/32
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Figure 2
Time-dependent VEGF stimulation of Src association with KDR/Flk-1. HUVECs were serum-starved and then 
treated with VEGF (15 ng/mL) for 0, 15, 30, 60, or 120 min. (A) Cell extracts from the indicated treatment conditions were 
immunoprecipitated using α-Src 2–17, and immunoblotted using α-KDR/Flk-1 (N-931) or α-Src 327. (B) Cell extracts from the 
indicated treatment conditions were immunoprecipitated using α-KDR/Flk-1 (N-931), and immunoblotted using α-phosphoty-
rosine (4G10), α-phosphotyrosine 419 Src, or α-KDR/Flk-1 (A-3). (C) Cell extracts from the indicated treatment conditions 
were immunoprecipitated using α-Src 2–17, and immunoblotted using α-Flt-1 (H-225) or α-Src 327. (D) Cell extracts from the 
indicated treatment conditions were immunoprecipitated using α-Flt-1 (H-225), and immunoblotted using α-phosphotyrosine 
(4G10), α-Src 327, or α-Flt-1 (H-225).
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Figure 3
GST pull-downs and Far Western blots indicate increased Src SH3-SH2 interaction with KDR/Flk-1 upon 
VEGF stimulation. (A) HUVECs were either serum-starved (0') or starved and then VEGF-treated (15 ng/mL for 15 min) 
(15'). The indicated GST-Src domain fusion proteins (see below) bound to glutathione-agarose beads were used (500 pmol 
equimolar amounts each), in pull-down incubations with equal amounts of protein lysate samples (500 µg each). The pull-down 
complexes were resolved on a 7% acrylamide SDS-PAGE gel and transferred to nitrocellulose. Immunoblotting was then per-
formed using α-KDR/Flk-1 (A-3) or α-Flt-1 (H-225). GU, GST-Src unique domain fusion protein; GU32, GST-Src unique SH3 
SH2 domain fusion protein; G32, GST-Src SH3 SH2 domain fusion protein. (B) Cell extract (pre-pull-down) input levels of 
phosphotyrosine KDR/Flk-1 and KDR/Flk-1, from HUVECs either serum-starved (0') or starved and then VEGF-treated (15'). 
(C) Cell extract (pre-pull-down) input levels of phosphotyrosine Flt-1 and Flt-1, from HUVECs either serum-starved (0') or 
starved and then VEGF-treated (15'). (D) HUVECs were serum-starved (-) or VEGF-treated with VEGF (15 ng/mL for 15 min) 
(+). The cell extracts were then immunoprecipitated using α-KDR/Flk-1 (N-931). The immunocomplexes were resolved on a 
7% acrylamide SDS-PAGE gel. Biotinylated GST and biotinylated GST-Src SH3-SH2 fusion protein were used in Far Western 
blotting. Detection was performed using horseradish peroxidase-conjugated ExtrAvidin®, followed by enhanced chemilumines-
cence detection reagents. Immunoprecipitation-Western blots for levels of phosphotyrosine KDR/Flk-1 and KDR/Flk-1 of the 
serum-starved (-) or VEGF-treated HUVEC (+) cell extracts were also performed in parallel.
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residues 951 and 996 (in the kinase insert domain), and
1054 and 1059 (in the C-terminal kinase domain) on
KDR/Flk-1 have also been demonstrated to be phosphor-
ylated [43]. Also, Takahashi and collaborators [44] have
shown that in cultured endothelial cells, tyrosine residues
1175 and 1214 are major phosphorylation sites. In a re-
cent study published by Meyer et al. [45], VEGF activation
of murine Flk-1 was found to stimulate Src activity; how-
ever, mutational analysis of tyrosine 1212 (homologous
tyrosine in murine Flk-1 to tyrosine 1214 in human KDR)
did not impair Src activation, providing an important clue
that tyrosine 1212 of murine Flk-1 might not be the major
tyrosine involved in binding interactions with Src.
Coimmunoprecipitation of Fyn and Yes with Flt-1
The observed association of Src with KDR/Flk-1 upon
VEGF stimulation and the lack of detectable association of
Src with Flt-1 upon VEGF stimulation prompted us to ex-
amine whether other Src family kinases (such as Fyn and
Yes) might be recruited in a similar or different manner
upon VEGF stimulation. HUVECs were serum-starved and
treated with VEGF 15 ng/mL for 15 min, and the cell ex-
tracts were immunoprecipitated with either α-Fyn or α-
Yes, and Western blotted for Flt-1. Unlike Src, Fyn and Yes
were found to preferentially associate with Flt-1, follow-
ing VEGF treatment (Fig. 4A and 4B). Concurrently, Flt-1
immunoprecipitation and Flt-1 tyrosine phosphorylation
was also detectable (Fig. 4C). In contrast, we did not ob-
serve any detectable amounts of Fyn or Yes coimmuno-
precipitating with KDR/Flk-1 upon VEGF treatment (Fig.
4A and 4B). Control experiments indicate that indeed, de-
spite our observation that Fyn and Yes did not seem to
coimmunoprecipitate with KDR/Flk-1, KDR/Flk-1 immu-
noprecipitation and KDR/Flk-1 tyrosine phosphorylation
was still detectable (Fig. 4D).
These results are consistent with previous findings by
Waltenberger and collaborators [46] who demonstrated
that Fyn and Yes exhibited increased levels of tyrosine
phosphorylation upon VEGF stimulation (using stably
transfected, VEGFR-overexpressing porcine aortic en-
dothelial cell lines). Interestingly, they observed that, in
porcine aortic endothelial cell lines stably overexpressing
Flt-1, increases in Fyn and Yes tyrosine phosphorylation
occurred in the VEGF-treated cells (2.4 fold and 2.1 fold,
respectively). Also, they noted that increases in Fyn and
Yes tyrosine phosphorylation did not occur upon VEGF
stimulation in the KDR/Flk-1-overexpressing cell line.
However, they did not examine Src in their study. Thus,
taken together, our data and this previous report indicate
that Src preferentially interacts with KDR/Flk-1, whereas
Fyn and Yes preferentially interact with Flt-1, following
VEGF stimulation.
A bit unexpectedly, through the course of our experiments
we have found that our detection of Flt-1 in the HUVECs
used here is somewhat better than has been reported in
many previous publications (Fig. 1B, 2D). We note that
the HUVECs utilized in our study are primary and early
passage cells, kindly provided by Dr. K. Patel. Also, they
are seeded from harvest initially in human serum rather
than fetal calf serum. Therefore, it is possible that they
might retain many endothelial specific markers (such as
Flt-1) at higher levels than might be present in HUVECs
utilized under different conditions.
It is also possible that, to some extent, the differences in
VEGF-induced signaling between Src compared to Fyn
and Yes may be due to the differential localization of the
Src family members. For example, perhaps Flt-l-Fyn/Yes
complexes localize to a greater extent to caveolae fractions
of cells, whereas KDR/Flk-1-Src complexes might be more
generally distributed in the plasma membrane. This may
allow for appropriate fine-tuning of differential signaling.
Notably, there is strong evidence supporting a model that
dually acylated (e.g., myristylated and palmitylated) Src
family kinases, which include all Src family kinases with
the exceptions of Src and Blk, have the potential to be lo-
calized to specific plasma membrane subdomains (such
as caveolae). On the other hand, Src itself, which is only
myristylated, has been reported to not localize in these
microcompartments [47,48]. Undoubtedly, post-transla-
tional modifications of proteins would play a very large
role in regulating spatial and temporal specificity in signal
transduction in these distinct microcompartments.
Conclusions
Our experiments have revealed several important features
of c-Src involvement in the early steps of VEGF-mediated
signaling in HUVECs. Of primary importance was the
finding that Src became associated preferentially with
KDR/Flk-1, rather than with Flt-1, upon VEGF stimulation
and VEGFR activation. This binding of Src to KDR/Flk-1
and subsequent activation of Src was enhanced by tyro-
sine phosphorylation of KDR/Flk-1.
We also observed that, although Src binds preferentially
to KDR/Flk-1, two other Src family members, Fyn and Yes,
bind preferentially to the Flt-1 receptor upon stimulation
of HUVECs with VEGF. These results are consistent with
previous results that indicate that Fyn and Yes exhibited
increased levels of phosphorylation upon VEGF stimula-
tion in porcine aortic endothelial cells stably overexpress-
ing Flt-1 [46]. This difference in specificities may be a key
mode of fine-tuning downstream signals capitalized on
by endothelial cells. In this manner, it is possible that en-
dothelial cells could appropriately gear their responses to-
wards induction of vascular permeability and
mitogenicity through signals transmitted by KDR/Flk-1BMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/32
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[31], or vascular remodeling and revascularization
through signals transmitted by Flt-1 [49], to meet the spe-
cific need of a tissue depending on local requirements.
Methods
Materials
Human recombinant VEGF-A165 and enolase were pur-
chased from Sigma. Polyclonal α-KDR/Flk-1 (N-931)
raised against amino acids 931–997 of Flk-1, monoclonal
α-KDR/Flk-1 (A-3) raised against amino acids 1158–1345
of the carboxyl terminus of Flk-1, polyclonal α-Flt-1 (H-
225) raised against amino acids 23–247 mapping within
the extracellular domain of Flt-1 of human origin, α-Fyn
(FYN3), and α-Yes (3) were purchased from Santa Cruz
Biotechnology. α-Src phosphotyrosine 419 antibody was
from Cell Signaling. α-Src monoclonal antibodies were
purified from hybridomas obtained from Quality Biotech
(α-Src 2–17) or from hybridomas provided by Dr. Joan
Brugge (α-Src 327). α-phosphotyrosine (4G10) was pro-
vided by Dr. Stephen Robbins.
Cell culture
Human umbilical vein endothelial cells (HUVECs) were
provided by Dr. Kamala Patel (University of Calgary).
Figure 4
Coimmunoprecipitation of Fyn with Flt-1, and Yes with Flt-1.HUVECs were serum-starved (-), or starved and then 
treated with VEGF (15 ng/mL for 15 min) (+). The cell extracts were then subjected to immunoprecipitation-Western blotting 
experiments. (A) Cell extracts from the indicated treatment conditions were immunoprecipitated using α-Fyn, and immunob-
lotted using α-Flt-1 (H-225), α-KDR/Flk-1 (A-3), or α-Fyn. (B) Cell extracts from the indicated treatment conditions were 
immunoprecipitated using α-Yes, and immunoblotted using α-Flt-1 (H-225), α-KDR/Flk-1 (A-3), or α-Yes. (C) Cell extracts 
from the indicated treatment conditions were immunoprecipitated using α-Flt-1 (H-225), and immunoblotted using α-phos-
photyrosine (4G10) or α-Flt-1 (H-225). (D) Cell extracts from the indicated treatment conditions were immunoprecipitated 
using α-KDR/Flk-1 (N-931), and immunoblotted using α-phosphotyrosine (4G10) or α-KDR/Flk-1 (A-3).
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These cells were isolated from human umbilical cord
veins by collagenase treatment as described previously
[50]. HUVECs were maintained in M199 medium (Gib-
co) containing 10% fetal bovine serum, 2.2 mg/mL sodi-
um bicarbonate, 2.4 µg/mL thymidine, 10 units/mL
heparin, 2 mM glutamine, and antibiotics (100 units/mL
penicillin, 100 µg/mL streptomycin) at 37°C in 5% CO2.
Immunoprecipitations
HUVECs were serum-starved for 24 h and then treated
with VEGF (15 ng/mL) for 0, 15, 30, 60, or 120 min. Cells
were washed two times with PBS on ice. The cells were
then scraped in 1 mL of 1% NP-40 lysis buffer (150 mM
NaCl, 50 mM Tris pH 7.5, 1% Nonidet P-40, 2 mM EDTA,
50 µg/mL leupeptin, 10 µg/mL aprotinin, 200 µM sodium
orthovanadate, 4 mg/mL p-nitrophenyl phosphate). The
scraped cells were briefly vortexed, and then incubated on
ice for 10 min. Cell extracts were then clarified by centrif-
ugation at 4°C, 10 000 × g for 10 min. Cell extract samples
for immunoprecipitation were precleared using 10 µL
packed Protein A/G (1:1) and mixing on a rotator at 4°C
30 min. Centrifugation at 14000 rpm in a cold microcen-
trifuge for 2 minutes was then conducted and the pre-
cleared cell extract supernatant was collected.
Immunoprecipitations were performed using 15 µg α-Src
2–17 per 1 mg cell extract, or 3 µg α-KDR or 3 µg α-Flt-1
per 1 mg extract, and 15 µL packed Protein G agarose. The
immunoprecipitations were mixed on a rotator at 4°C for
2 h. The immune complexes were washed 3 times with 1%
NP-40 lysis buffer. Samples for Westerns were boiled for 5
min in 1X Laemmli's sample buffer, and resolved on 7%
or 10% acrylamide SDS-PAGE gels.
c-Src Kinase Activity Assays
HUVECs were either serum-starved for 24 h, or starved
and then treated with VEGF (15 ng/mL). Cell lysates of
these samples were then immunoprecipitated using α-
KDR/Flk-1,  α-Flt-1, or rabbit nonimmune IgG (rabbit
IgG). The immune complexes were washed 3 times with
0.8 mL of 1 % NP-40 lysis buffer, and once with 0.8 mL
Src kinase buffer (20 mM Tris pH 7.2, 5.0 mM MnCl2) and
put on ice for 5 min. The pellets were then centrifuged and
the supernatant buffer aspirated. Each kinase reaction was
started by the addition of 33 µL Src kinase reaction hot
mix (consisting of 30 µL of Src kinase buffer, 2 µL of 2.5
µg/mL enolase, and 1 µL (10 µCi) of [γ-32P]ATP (>3000
Ci/mmol). The reaction was incubated at 30°C for 20
min. The reactions were then stopped by the addition of
33 µL of 2X Laemmli's sample buffer and boiled for 5
min. Samples were resolved on 10% SDS-PAGE gels. The
gels were treated with 1 M KOH at 55°C for 1 h after elec-
trophoresis to remove background due to serine phospho-
rylation [51]. The gels were dried and exposed to
autoradiographic film. Band intensities were quantified
by densitometry of the autoradiogram.
GST-Src domain fusion constructs and expression
The required Src domain cDNA fragments were generated
by restriction digestion from pBA3CS, which contained
full-length wild type human c-Src cDNA. pG-U contains
the human c-Src unique domain (nt 1–170, aa 1–57) ob-
tained by restriction digestion of pBA3CS-human c-Src us-
ing NcoI and NotI. pG-U32 contains human c-Src unique,
SH3, and SH2 domains (nt 1–775, aa 1–258) obtained by
restriction digestion using NcoI and EcoNI. pG-32 con-
tains human c-Src SH3 and SH2 domains (nt 170–775, aa
57–258) obtained by restriction digestion using NotI and
EcoNI. The Src cDNA fragments above were treated with
Klenow to blunt their ends before ligation in frame into
pGEX-2T. Each pGEX-Src fusion-containing E. coli BL21
clone was cultured in 10 mL 2x YTA broth (16 g/L tryp-
tone, 10 g/L yeast extract, 5 g/L NaCl, 100 µg/mL ampicil-
lin, pH 7.0) overnight at 30°C, shaking at 250 rpm. The
starter culture was diluted 1:100 into 400 mL of fresh
2xYTA broth and grown at 30°C, shaking at 250 rpm, un-
til A600 reached 0.5–2. The culture was then induced by
the addition of isopropyl-β-D-thiogalactoside to a final
concentration of 0.2 mM for 3 h at 30°C, shaking at 250
rpm. GST-Src fusion protein harvesting and purification
was carried out following pGEX vector supplier's instruc-
tions (Amersham Pharmacia Biotech).
GST-Src domain fusion protein pull-downs of KDR/Flk-1
HUVECs were starved in serum-free medium for 24 h and
then treated with VEGF (15 ng/mL) for 0 or 15 min. Equi-
molar amounts of the various GST-Src domain fusion pro-
teins (500 pmol) bound to Glutathione-agarose beads
were used in pull-down incubations (at 4°C for 3 hours)
with equal amounts of cell extracts (500 µg). The fusion
protein complexes were pelleted by centrifugation and
washed three times with lysis buffer. The washed fusion
protein pellets were boiled in 1X Laemmli's sample buff-
er, resolved on a 7% acrylamide SDS-PAGE gel, and trans-
ferred to nitrocellulose. Afterward, immunoblotting was
performed and results were developed by using enhanced
chemiluminescence (Amersham).
Far western blotting
GST-Src domain fusion proteins were biotinylated at
room temperature for 3 h with biotinamidocaproate-N-
hydroxysuccinimide ester (100 µg/mL, Sigma) at a fusion
protein concentration of 2 mg/mL in 0.1 M sodium bo-
rate, pH 8.8. Biotinylated protein was purified extensively
by washes using PBS, pH 7.5, 2 mM dithiothreitol
through a MICROSEP microconcentrator (Filtron Tech-
nology, according to manufacturer's instructions). The fi-
nal biotinylated protein products were used at
concentrations of 2 µg/mL in PBS, 1 mM dithiothreitol, in
Far Western blotting of nitrocellulose membranes. Bioti-
nylated probes were detected with horseradish peroxi-
dase-conjugated ExtrAvidin® (Sigma) at 1:2000 dilutionBMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/32
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in PBS, 3 % BSA, 0.05% Tween-20. Results were devel-
oped by reaction using enhanced chemiluminescence
(Amersham).
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